Skip to main content
. 2014 Jan 14;289(10):6681–6694. doi: 10.1074/jbc.M113.487348

FIGURE 2.

FIGURE 2.

Activation of synaptic NMDARs increases surface expression of GABABRs. A, effects of glycine on GABAB1, GABAB2, and the AMPAR subunit GluA2 assessed by surface biotinylation. Cultured cortical neurons were treated with 200 μm glycine for 3 min and then incubated for 5 or 20 min without glycine before surface biotinylation and harvesting. Blots were probed with anti-GABAB and anti-GluA2 antibodies and reprobed with anti-β-actin antibody to ensure equal loading and the specificity of surface biotinylation. B, quantification of the effect of chemLTP on GABAB1 and GABAB2. C, validation of chemLTP showing increased GluA2 protein surface expression. The results shown are the ratios of at least three independent experiments (n = 3). **, p ≤ 0.01 and ***, p ≤ 0.005 compared with control (Student's t test). D, GABABR endocytosis and recycling was measured by the loss of internalized GABABR specifically labeled with cleavable (S = S linked) biotin. Cortical cultures were surface-biotinylated as described above, and cells were activated by chemLTP protocol and incubated for 5 or 20 min to allow internalized receptors to recycle before cleavage of surface biotin. Residual biotinylated (internal) receptors were then isolated from cells by streptavidin pulldown, and GABABR subunits were detected by Western blotting. Blots were probed with anti- GABAB1 and anti-GABAB2 antibodies and reprobed with anti-β-actin antibody to ensure equal loading and the specificity of biotinylation. E, quantification of the effect of chemLTP on GABAB1 and GABAB2 rate of disappearance of biotinylated GABABRs provides a measure of receptor recycling. Leupeptin was included throughout the treatments to block any protein degradation or loss of internalized receptors. The results shown are the ratios of at least three independent experiments (n = 3). **, p ≤ 0.01 and ***, p ≤ 0.005 compared with control (Student's t test). § (p ≤ 0.005), significant differences between with and without AP5 treatments.